Related Experiment Video
Updated: May 30, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.6K
EValuating Glucose ContrOL Using a Next-GeneraTION Automated Insulin Delivery Algorithm in Patients with Type 1 and
Tom Wilkinson1, Renee Meier1, Niranjala Hewapathirana2
1Department of Paediatrics, University of Otago, Christchurch, New Zealand.
Diabetes Technology & Therapeutics
|January 27, 2025
Summary
A new automated insulin delivery (AID) algorithm for Omnipod shows promise for managing diabetes. This advanced system effectively reduced high blood glucose levels in both type 1 and type 2 diabetes patients.
Area of Science:
- Endocrinology and Metabolism
- Biomedical Engineering
- Diabetes Technology
Background:
- Automated insulin delivery (AID) systems aim to improve glycemic control in diabetes.
- Evaluating next-generation algorithms is crucial for advancing diabetes management.
- Omnipod's AID system offers a wearable, tubeless insulin pump option.
Purpose of the Study:
- To assess the feasibility and efficacy of a next-generation Omnipod AID algorithm.
- To evaluate the algorithm's performance in individuals with type 1 and type 2 diabetes.
- To compare outcomes with and without manual bolus delivery.
Main Methods:
- Multi-phase study including a run-in period, a hotel setting phase (type 1 only), and an outpatient phase.
- Participants used the Omnipod AID system for up to 6 weeks.
- Continuous glucose monitoring (CGM) data were analyzed, with participants alternating manual bolus delivery.
Main Results:
- Significant reduction in time spent with glucose readings >250 mg/dL in both type 1 and type 2 diabetes patients.
- Outpatient hyperglycemia decreased from 33.5% to 9.4% (with bolus) and 14.3% (without bolus) in type 1 diabetes.
- Outpatient hyperglycemia decreased from 20.8% to 7.7% (with bolus) and 10.5% (without bolus) in type 2 diabetes.
- Time below 70 mg/dL remained consistently low (<4%) across all study phases.
- No adverse events were reported during the study.
Conclusions:
- The next-generation Omnipod AID algorithm is feasible for individuals with type 1 and type 2 diabetes.
- The algorithm demonstrates effective glucose control, reducing hyperglycemia.
- Further research may explore long-term outcomes and wider adoption of this AID technology.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
01:22Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
01:22Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
01:16Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
01:27Insulin Formulations: Types and Delivery
162
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
162
01:15Diabetes: Symptoms, Diagnosis, and Complications
500
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
500